CAR-T cell therapy for recurrent grade 4 brain tumors
Part of Cancer clinical trials.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a grade 4 glioma (glioblastoma or similar) that has returned or worsened after standard treatments like radiation and temozolomide.
- Your tumor must have at least 30% of cells positive for the B7-H3 protein (tested on a tissue sample).
- You are not a candidate for another surgery to remove the tumor.
- You have good organ function (heart, lungs, blood counts, kidney, liver).
- You have not received CAR-T therapy or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new treatment called TH-CAR-027 for people with grade 4 gliomas (a type of aggressive brain tumor) that have come back or grown after standard therapy. The treatment uses your own immune cells, which are modified in a lab to target a protein called B7-H3 on tumor cells, and then given back to you. The goal is to see if this therapy can help control the tumor.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.